Organogenesis (ORGO) Q3 2026 Earnings Call Transcript
Organogenesis (ORGO) reported Q3 2026 revenue of $45.5M, down 70% YoY but up 6% QoQ. The company gained market share, with Apligraf and other products showing growth. Amnuvx BLA review delayed due to FDA requests. ORGO remains optimistic about its position in the skin substitute market and future growth.
How this was made
The 30-second read
Why it matters
The earnings miss is likely to trigger short‑term price weakness, but the company’s pipeline announcements could mitigate downside over the longer term.
Market read
Earnings data provides fresh material for traders; the magnitude of the decline makes the news highly relevant for ORGO investors.
What to watch
The upcoming FDA review of the Amnuvx program and new clinical data for PuraPly AM may provide future upside.
Background
Organogenesis reported a steep YoY revenue decline in its Q3 2026 earnings call, highlighting CMS policy impacts and ongoing FDA submissions.
Ticker impact
Q3 2026 earnings call disclosed net product revenue of $45.5M, down 70% YoY, with sequential 6% revenue increase.
likely downside pressure as investors react to the 70% YoY revenue drop.
The disclosed revenue decline is material and new; market will price in the weak top line despite slight quarter‑over‑quarter improvement.
Market effects
Wound‑care and regenerative‑medicine sector may see broader scrutiny as CMS policy changes continue to pressure revenues.
U.S. biotech and medical‑device stocks could face short‑term volatility.
Limited to investors focused on niche regenerative‑medicine companies.
Counterpoint
Quarter‑over‑quarter revenue growth suggests a turnaround narrative that could be undervalued.
Key entities
- CompanyOrganogenesis
Regenerative‑medicine firm focused on skin substitutes.
